On December 18, 2012, I published a Seeking Alpha article naming Cellceutix (OTCQB:CTIX) as my Stock of the Year for 2013. Six months into the year, let's take an updated look why CTIX is still my 2013 Stock of the Year.
The recent offer by Amgen (NASDAQ: AMGN) to buy Onyx Pharmaceuticals (NASDAQ: ONXX) is the latest in a string of acquisitions that has cancer drug makers on the hot list again. Effective oncology drugs can command a premium like no other, which is why I maintain an extremely bullish stance on Cellceutix as one of the most compelling biotechnology companies today and for the future. Shares have spiked to deliver gains as high as...
Only subscribers can access this article, which is part of the PRO research library covering 3,770 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: